Average Co-Inventor Count = 2.45
ph-index = 2
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Celgene Quanticel Research, Inc. (8 from 106 patents)
2. Celgene Corporation (1 from 549 patents)
9 patents:
1. 11464771 - Bromodomain and extra-terminal protein inhibitor combination therapy
2. 10960005 - Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
3. 10881655 - Bromodomain and extra-terminal protein inhibitor combination therapy
4. 10849898 - Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas
5. 10576075 - Bromodomain and extra-terminal protein inhibitor combination therapy
6. 10548896 - Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas
7. 10543213 - Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
8. 10328077 - Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
9. 10166227 - Bromodomain and extra-terminal protein inhibitor combination therapy